Alexandra M. Levine, M.D., Chief Medical Officer, City of Hope

The incidence rates for colorectal cancer have declined steadily over the past 20 years, owing in large part to improved screening and preventive measures and greater awareness of the disease. Still, it remains the third most common malignancy among both men and women. In response, City of Hope maintains an aggressive, collaborative approach to managing and treating colorectal cancer.

Using a comprehensive array of the latest treatment technologies, our specialists team with patients and their physicians, working together to make informed treatment decisions. This collaborative partnership allows the team to draw from the latest technologies at City of Hope — including robotic-assisted surgical techniques, advanced radiation therapies such as TomoTherapy and the newest targeted therapeutics — to tailor treatments to each patient’s specific needs.

In addition, City of Hope’s practice of addressing every aspect of the patient’s well-being ensures they are fully supported throughout the treatment and recovery process.

Using this collaborative approach, City of Hope aims to empower patients and physicians throughout the treatment process and maximize the potential for positive outcomes.